Aurisco Pharmaceutical Co Ltd (605116) — Capital Reinvestment Ratio
Latest as of December 2024:
1.63x
Aurisco Pharmaceutical Co Ltd (605116) has a Capital Reinvestment Ratio of 1.63x as of December 2024, meaning it reinvests 2% of its operating cash flow (CN¥332.41 Million) in capital expenditures (CN¥540.28 Million). See how much free cash does Aurisco Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.63x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥332.41 Million
CNY
Capital Expenditures
CN¥540.28 Million
CNY
Data as of
Dec 2024
Most recent filing
Aurisco Pharmaceutical Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks Aurisco Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Aurisco Pharmaceutical Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for Aurisco Pharmaceutical Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see 605116 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.63x | CN¥332.41 Million | CN¥540.28 Million | ▲ +105.2% |
| 2023 | 0.79x | CN¥385.61 Million | CN¥305.48 Million | ▼ -39.0% |
| 2022 | 1.30x | CN¥166.41 Million | CN¥216.23 Million | ▲ +4.5% |
| 2021 | 1.24x | CN¥201.57 Million | CN¥250.61 Million | ▲ +67.9% |
| 2020 | 0.74x | CN¥214.48 Million | CN¥158.80 Million | ▲ +83.8% |
| 2019 | 0.40x | CN¥179.90 Million | CN¥72.47 Million | ▼ -53.0% |
| 2018 | 0.86x | CN¥109.77 Million | CN¥94.14 Million | ▼ -5.1% |
| 2017 | 0.90x | CN¥117.91 Million | CN¥106.60 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow